Prostatype Genomics

Prostatype Genomics AAQS

The The AAQS of Prostatype Genomics (PROGEN.ST) as of Oct 21, 2026 is 5. In the previous year, The AAQS was 5.00 — a change of 0.00% (lower).

AAQS

5

YoY

0.00%

Last updated:

Prostatype Genomics has a current AAQS of 5.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Prostatype Genomics in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Prostatype Genomics AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
5.00 SEK
Jan 1, 2019
5.00 SEK
Jan 1, 2020
5.00 SEK
Jan 1, 2021
5.00 SEK
Jan 1, 2022
5.00 SEK
Jan 1, 2023
5.00 SEK
Jan 1, 2024
5.00 SEK
Jan 1, 2025
5.00 SEK
The Prostatype Genomics AAQS history
YEARAAQSYoY
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
5—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

The AAQS of Prostatype Genomics is 5 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Prostatype Genomics

All Key Metrics — Prostatype Genomics